← The Wire·Breaking·Earnings·

Celcuity submits FDA application for REVTORPYK in PIK3CA-mutant breast cancer

Celcuity submitted a supplemental New Drug Application to the FDA seeking approval for REVTORPYK (gedatolisib) in patients with HR+/HER2-, PIK3CA-mutant locally advanced or metastatic breast cancer after progression. The filing creates an FDA-review catalyst for CELC.

The story

Celcuity said on Aug. 26, 2026 that it submitted the sNDA to the FDA for REVTORPYK, also known as gedatolisib. The proposed use covers patients with hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer carrying a PIK3CA mutation after progression on or after prior treatment.

The named company is Celcuity Inc. (Nasdaq: CELC), and the regulatory mechanism is a supplemental application for an existing product rather than a new molecular entity filing. The next concrete developments are FDA validation or acceptance of the submission, any assigned review timeline, and subsequent regulatory communications.

Our read · Wed, Aug 26

The sNDA moves CELC into an FDA-review catalyst, with the upside case tied to regulatory acceptance and eventual approval rather than the filing itself.

Why. The filing gives CELC a defined regulatory pathway, but the announcement supplies no FDA acceptance, review date, efficacy figures, or safety data to support a conviction trade. The immediate read is therefore event-driven and positive in setup, with the decisive information still ahead in the FDA process.

Both cases

The case it holdsFDA acceptance and a subsequent approval for the PIK3CA-mutant breast-cancer indication would expand the commercial opportunity for REVTORPYK.
The case it breaksThe filing alone is not an approval, and there is no clinical or regulatory evidence showing that FDA acceptance or approval is assured.

What could change this view: The trade fails if the FDA declines to accept the sNDA, requests additional information, or the eventual review does not support the proposed indication.

Celc stock page →
Your side is graded privately against closes after 10 trading days. Research, not advice.

Who reported it · 1

Keep reading

Latest on the Wire

AMD shares fall 11% after Hunterbrook warns over China linksWalmart raises full-year outlook as e-commerce wins shoppersAnthropic IPO could become the largest in US history on ThursdayContinuing claims rise as Goldman sees Fed hikes in December and MarchPIF Tower in Riyadh reportedly damaged in second Houthi attackContinue on the Wire →

Top this week

Nvidia allies lobby board to bring back Jensen Huang as CEONvidia chair rules out Huang return as CEO after 75% sales outlookAnthropic Said to Guide IPO Pricing Above Market RangeNvidia interim CEO Colette Kress faces first earnings test after HuangNvidia CEO Jensen Huang reportedly resigns as US-China tensions rise
The Wire at 7 AM ET, free. Top stories with a bull and a bear case on each, every morning. No account needed.

About this report

Reported by GlobeNewswire as Celcuity Submits sNDA to FDA for REVTORPYK™ (gedatolisib) for HR+/HER2-, PIK3CA Mutant Locally Advanced or Metastatic Breast Cancer, . Who answers for this

The only report in this record. Closes are licensed end-of-day data from Databento; the move after a story is its first close against the close before it. How this is decided →

Kept as written · your side, if you take one, is graded privately against licensed closes after 10 trading days · nothing here is advice · How the Wire is made →